Approximately 1 in 2 North Americans will develop cancer in their lifetime. Fortunately, improvements in medical care have led to people living longer than ever after receiving a cancer diagnosis. However, many of the treatments that have improved cancer survival also damage and impair the function of the heart, lungs, blood vessels, and skeletal muscles (called cardiovascular toxicity) which may lead to cardiovascular disease (CVD). Today, cancer-related CVD is a major source of chronic morbidity and a leading cause of mortality in select survivor groups – representing a major burden to survivors, the healthcare system, and society. Despite these devastating consequences, highly effective approaches to cardiotoxicity risk screening, prevention, and treatment in cancer survivors have not been established.
- Understanding the mechanisms and time course of CVD development in cancer survivors.
- Improving the accuracy of CVD risk prediction and stratification approaches in cancer survivors.
- Developing targeted exercise-based strategies to prevent and treat cancer-related CVD in at-risk and affected populations.
- Implementing our work within clinical and community settings.
- BIOMARKER VALIDATION – Investigating the independent and additive value of cardiorespiratory fitness (measured as VO2peak) as a biomarker for identifying and stratifying cancer survivors according their risk for CVD development, progression, events, and mortality.
- PRECISION PROFILING – Defining phenogroups of survivors on the basis shared risks and mechanisms (i.e., common risk factors, mediators, and time-course) of CVD pathogenesis.
- CVD SCREENING & RISK STRATIFICATION – Validating tools for CVD risk screening and stratification to enhance the identification, interpretation, and communication of CVD-related risks within at-risk and affected phenogroups of cancer survivors.
- PRECISION EXERCISE THERAPY – Developing exercise therapy-based, multimodal treatment strategies targeting phenogroup-specific (i) determinants of cardiorespiratory fitness and (ii) mechanisms of CVD risk and progression.